A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an unusually ambitious goal: building AI systems capable of improving themselves ...

AI startup Recursive has officially emerged from stealth, calling recursive self-improvement the "fastest path to superintelligence." "The fastest path to superintelligence will be realized by AI that ...

If you have played Plants vs Zombies and liked it, you’ll surely find Merge and Fight an interesting experience. This game merges the best points of a tower defense game and Plants vs Zombies to give ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Merge sort is entirely different than the sorting algorithms we’ve seen so far, and it represents an important class of algorithms—divide-and-conquer algorithms. Divide-and-conquer algorithms work by ...

Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Utah-based Recursion, a clinical-stage biotech company specialising in drug discovery, has entered into a definitive agreement to merge with Oxford-based Exscientia, a clinical-stage drug design and ...

On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...